Piscataway, NJ (PressExposure) September 01, 2009 -- Internationally recognized biology contract research organization (CRO), GenScript USA Inc. announced today that the company has established biology research collaboration with Roche R&D Center (China) Ltd (RRDCC), a subsidiary of world leading pharmaceutical manufacturer Roche since early 2009. Under the agreement, GenScript is set to provide assay development services for potential drug targets in line with Roche's drug development portfolio.
Recognizing the distinct advantages that CRO providers offer, many pharmaceutical companies have adapted outsourcing strategy to increase productivity and offset cost. "After the success of medicinal chemistry outsourcing, biology CRO is becoming a new trend in drug discovery. We expect a fruitful collaboration with GenScript in assay development", remarked Dr. Li Chen, Chief Scientific Officer of Roche R&D Center in China. "Being the first drug discovery based R&D center established in China by a leading multinational pharmaceutical company, RRDCC is taking the lead again in expanding into discovery biology arena. We appreciate the confidence that RRDCC has shown in GenScript, and believe that the collaboration will mutually benefit us." said Dr. Frank Zhang, Chief Executive Officer of GenScript.
GenScript is a contract research organization (CRO) specialized in biological research and drug discovery services. Its service portfolio includes bio-reagent services, assay development & screening, lead optimization, and antibody drug development. The renowned one-stop bio-reagent services include custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development. Headquartered in Piscataway, New Jersey, GenScript has become a world-leading Biology CRO and the largest gene synthesis supplier in the USA, with subsidiaries in France, Japan, and China. Recently, the company received $15M investment led by Kleiner Perkins Caufield & Byers (KPCB) to expand its biology and bio-reagent services in drug discovery and development.